Application of apatinib after multifaceted therapies for metastatic breast cancer.
Application of apatinib after multifaceted therapies for metastatic breast cancer.
复制标题
阿帕替尼在转移性乳腺癌多方面治疗后的应用
DOI：
10.21037/tcr-19-2588
复制
发表时间：
2020-08
影响因子：
0.9
通讯作者：
Cheng J
中科院分区：
文献类型：
--
作者：
Wang J;Chen Y;Chen R;Wu L;Cheng J
阿帕替尼是一种口服小分子酪氨酸激酶抑制剂（TKI），对血管内皮生长因子受体2（VEGFR-2）具有高度特异性。本研究探讨了阿帕替尼在多方面治疗无效的转移性乳腺癌（MBC）患者中的疗效和毒性。本研究共纳入61例对既往多方面化疗无反应的MBC患者。治疗方案为阿帕替尼联合化疗或阿帕替尼单独给药，剂量范围为250 mg/2天至500 mg/天。无进展生存期（PFS）、客观缓解率（ORR）、疾病控制率（DCR）和毒性被用作结局指标。在61例患者中，14例患者（23.0%）观察到部分缓解（PR），30例患者（49.2%）观察到疾病稳定（SD），17例患者（27.8%）观察到疾病进展（PD）。DCR为44/61（72.1%），ORR为14/61（23.0%）。在44例达到PR或SD的患者中，中位PFS为4个月15天。发现颅内转移患者从阿帕替尼中获益。此外，11例患者接受了下一代测序（NGS），其中5例有P53突变。在这5例病例中，ORR和DCR分别为0%和20.0%。6例野生型P53阳性患者中，ORR为50.0%，DCR为100.0%。多因素回归分析发现高血压是影响DCR的独立预后因素。阿帕替尼在多方面治疗无效的MBC患者中显示出良好的疗效和可控的毒性。
Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This study explored the efficacy and toxicity of apatinib in patients with metastatic breast cancer (MBC) who failed to respond to multifaceted therapy. A total of 61 patients with MBC who were unresponsive to previous multifaceted chemotherapy were included in this study. The treatment regimens were either a combination of apatinib and chemotherapy or apatinib administered singly with a dose range of 250 mg every second day to 500 mg per day. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and toxicity were used as outcome measures. Of the 61 patients, partial response (PR) was observed in 14 patients (23.0%), stable disease (SD) was observed in 30 patients (49.2%), and progressive disease (PD) was observed in 17 patients (27.8%). The DCR was 44/61 (72.1%), and the ORR was 14/61 (23.0%). Of the 44 patients who achieved PR or SD, the median PFS was 4 months and 15 days. Patients with intracranial metastases were found to benefit from apatinib. Furthermore, 11 patients underwent next generation sequencing (NGS) and 5 of these had a P53 mutation. Of those 5 cases, the ORR and DCR were 0% and 20.0%, respectively. Of the 6 cases with wild-type P53, the ORR was 50.0%, and the DCR was 100.0%. Multivariate regression analysis found that hypertension was an independent prognostic factor of better DCR. Apatinib showed good efficacy and manageable toxicity in patients with MBC that had not responded to multifaceted therapy.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
9.2
作者：
ter Veer, Emil;Mohammad, Nadia Haj;van Valkenhoef, Gert;Ngai, Lok Lam;Mali, Rosa M. A.;van Oijen, Martijn G. H.;van Laarhoven, Hanneke W. M.
通讯作者：
van Laarhoven, Hanneke W. M.
影响因子：
6.2
作者：
Ferrero, Jean-Marc;Hardy-Bessard, Anne-Claire;Largillier, Remy
通讯作者：
Largillier, Remy
影响因子：
5.8
作者：
Tong, Xiu-zhen;Wang, Fang;Fu, Li-wu
通讯作者：
Fu, Li-wu
影响因子：
11.2
作者：
Mi YJ;Liang YJ;Huang HB;Zhao HY;Wu CP;Wang F;Tao LY;Zhang CZ;Dai CL;Tiwari AK;Ma XX;To KK;Ambudkar SV;Chen ZS;Fu LW
通讯作者：
Fu LW